- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04226027
Dynamically Tailored Behavioral Interventions in Diabetes
Dynamically Tailoring Interventions for Problem-Solving in Diabetes Self-Management Using Self-Monitoring Data - a Randomized Controlled Trial (RCT)
Studienübersicht
Detaillierte Beschreibung
One of the main difficulties in managing diabetes is that each affected individual requires personally tailored combination of diet, exercise, and medication to effectively control their blood sugar. Rather than strictly following a doctor's prescription, individuals need to carefully examine their lifestyle choices and their impact on their health. Independent learning, experimentation and problem solving become of great importance. However, they can be challenging for individuals with diabetes. In this project, the investigators will refine and evaluate a novel intervention for diabetes self-management that uses computational analysis of self-monitoring data to help individuals with type 2 diabetes identify what daily activities, including consumption of meals, physical activity, and sleep, have impact on blood glucose levels, and suggest modifications to these daily activities to improve blood glucose levels.
Growing evidence highlights significant differences in glycemic function and cultural, social, and economical circumstances of individuals with type 2 diabetes (T2DM) that impact their self-management. Precision medicine strives to personalize medical treatment to an individual's genetic makeup, computationally discovered clinical phenotypes and lifestyle. Studies showed the benefits of tailoring not only medical treatment, but also behavioral interventions. Yet, currently, personalization of self-management in T2DM requires each individual to engage in discovery, reflection, and problem-solving-critical but cognitively demanding activities-or to rely on their healthcare providers. Both of these may present considerable barriers to individuals from medically under-served low income communities. Mobile health (mHealth) solutions in T2DM bring promise of reaching wider populations in need of self-management; however, few such solutions provide assistance with personalizing self-management behaviors. Ongoing efforts on personalizing behavioral interventions outside of T2DM focus on tailoring behavior modification techniques to individuals' psycho-social characteristics, such as self-efficacy ), and tailoring delivery of intervention to individuals' context rather than on personalizing self-management strategies.
The ongoing focus of this research is on developing informatics interventions for diabetes self-management, with a specific focus on discovery with self-monitoring data and on problem-solving for improving glycemic control. In the proposed research the investigators introduce T2.coach, an mHealth intervention that uses computational analysis of self-monitoring data to identify behavioral patterns associated with poor glycemic control and formulate personalized behavioral goals for changing problematic behaviors. This study will evaluate T2.coach's efficacy in a two-arm RCT with stratified randomization conducted with Clinical Directors Network (CDN), a well-recognized primary care practice-based research network (PBRN) of Federally Qualified Health Centers (FQHCs), and Agency for Healthcare Research and Quality (AHRQ)-designated Center of Excellence (P30) for Practice-based Research and Learning.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- Columbia University Irving Medical Center
-
Kontakt:
- Olena Mamykina, PhD
- Telefonnummer: 212-305-3923
- E-Mail: om2196@cumc.columbia.edu
-
New York, New York, Vereinigte Staaten, 10018
- Rekrutierung
- Clinical Directors Network
-
Kontakt:
- Andrea Cassells, MPH
- Telefonnummer: 212-382-0699
- E-Mail: acass@cdnetwork.org
-
Unterermittler:
- Andrea Cassells, MPH
-
Hauptermittler:
- Jonathan Tobin, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patient of the health center for ≥ 6 months and a diagnosis of T2DM
- HbA1c ≥ 8.0,
- Aged 18 to 65 years
- Attends diabetes education program at the health center
- Owns a basic mobile phone
- Proficient in either English or Spanish
Exclusion Criteria:
- Pregnant
- Presence of severe cognitive impairment (recorded in patient chart),
- Existence of other serious illnesses (e.g. cancer diagnosis with active treatment, advanced stage heart failure, dialysis, multiple sclerosis, advanced retinopathy, recorded in patient chart),
- Plans for leaving the FQHC in the next 12 months,
- Participation in the previous trial of diabetes self-management technologies
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: T2.coach
Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center) and are asked to use T2.coach for 6 months.
|
T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep.
All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals.
Examples of behavioral goals include the following: "For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice.
Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple."
The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement.
|
Kein Eingriff: Control
Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in HbA1c value
Zeitfenster: Baseline, 6 months, 12 months
|
Hemoglobin A1c
|
Baseline, 6 months, 12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
DPSI Score
Zeitfenster: Baseline, 6 months, 12 months
|
Diabetes Problem-Solving Inventory (DPSI) is a 9-item, open-ended questionnaire.
Answers are coded on a Likert 5-point scale (1-very poor strategy; 5-excellent strategy).
The final score ranges from 1 (lowest) to 5 (highest) and an overall score ≤3 indicates poor diabetes problem solving, so a higher score indicates a better outcome.
|
Baseline, 6 months, 12 months
|
SCA-I Score
Zeitfenster: Baseline, 6 months, 12 months
|
Diabetes Self-Care Inventory (SCA-I) is a 15-item 5-point Likert scale (1-never engage; 5-always engage) for measuring different aspects of diabetes self-care.
The final score ranges from 1 (lowest) to 5 (highest) with a higher score indicating better self-care (better outcome).
|
Baseline, 6 months, 12 months
|
DSES Score
Zeitfenster: Baseline, 6 months, 12 months
|
Diabetes Self-Efficacy Scale (DSES) is a 15-item 10-point Likert scale (1-not at all confident; 4-totally confident) that measures the belief that one can self-manage one's own health, adapted to diabetes.
The final score ranges from 1 (lowest) to 4 (highest) with a lower score indicating poor self-efficacy (worse outcome).
|
Baseline, 6 months, 12 months
|
PAID Score
Zeitfenster: Baseline, 6 months, 12 months
|
Problem Areas in Diabetes (PAID) is a 20-item 5-point Likert scale (0-not a problem; 4-very serious problem) that measures the emotional aspect of living with diabetes.
The final score ranges from 0 (lowest) to 80 (highest), with a higher score indicating greater emotional discomfort (worse outcome).
|
Baseline, 6 months, 12 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Olena Mamykina, PhD, Columbia University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AAAS5528
- R01DK113189 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Typ 2 Diabetes
-
Bnai Zion Medical CenterUnbekannt
-
Jeil Pharmaceutical Co., Ltd.Noch keine RekrutierungTyp 2 Diabetes mellitusKorea, Republik von
-
Nanjing First Hospital, Nanjing Medical UniversityRekrutierung
-
Sun Yat-sen UniversityGuangdong Provincial Hospital of Traditional Chinese Medicine; The Third Affiliated... und andere MitarbeiterRekrutierung
-
BayerAktiv, nicht rekrutierend
-
TakedaAbgeschlossen
-
Shanghai HEP Pharmaceutical Co., Ltd.ZurückgezogenTyp-2-Diabetes-Patienten
-
Nanjing First Hospital, Nanjing Medical UniversityAktiv, nicht rekrutierendTyp 2 Diabetes mellitusChina
-
Handok Inc.Abgeschlossen
-
Rush University Medical CenterZurückgezogen
Klinische Studien zur T2.coach
-
Bryan AllenNational Cancer Institute (NCI); Holden Comprehensive Cancer CenterRekrutierungSarkom | Magnetresonanztomographie | StrahlentherapieVereinigte Staaten
-
The University of QueenslandRekrutierung
-
Vanderbilt University Medical CenterAbgeschlossenFettleibigkeit, KindheitVereinigte Staaten
-
Syracuse VA Medical CenterAbgeschlossen
-
VA Office of Research and DevelopmentDefense Centers of Excellence for Psychological Health and Traumatic Brain...RekrutierungPosttraumatische BelastungsstörungVereinigte Staaten
-
Insud PharmaAbgeschlossen
-
Central Hospital, Nancy, FranceAbgeschlossenHerztransplantation | Akute TransplantatabstoßungFrankreich
-
Association de Recherche Bibliographique pour les...Centre Hospitalier Universitaire de Nice; Centre Hospitalier Princesse GraceAbgeschlossen
-
Johns Hopkins Bloomberg School of Public HealthNational Cancer Institute (NCI)AbgeschlossenGebärmutterhalskrebs | Brustkrebs | DarmkrebsVereinigte Staaten
-
European e-Learning School in Obstetric AnesthesiaNoch keine Rekrutierung